	US 12,201,614 B2
	Methods for treating heterotopic ossification
Clarissa Desjardins, Westmount (CA); Donna Roy Grogan, Boston, MA (US); Jeffrey Neal Packman, Weston, MA (US); and Mark Harnett, Stow, MA (US)
Assigned to Clementia Pharmaceuticals Inc., Montreal (CA)
Filed by Clementia Pharmaceuticals Inc., Montreal (CA)
Filed on Jun. 28, 2024, as Appl. No. 18/758,242.
Application 18/758,242 is a continuation of application No. 18/637,711, filed on Apr. 17, 2024.
Application 18/637,711 is a continuation of application No. 18/182,463, filed on Mar. 13, 2023.
Application 18/182,463 is a continuation of application No. 16/950,604, filed on Nov. 17, 2020, granted, now 11,622,959, issued on Apr. 11, 2023.
Application 16/950,604 is a continuation of application No. 16/308,012, granted, now 10,864,194, issued on Dec. 15, 2020, previously published as PCT/CA2017/050701, filed on Jun. 8, 2017.
Claims priority of provisional application 62/347,381, filed on Jun. 8, 2016.
Prior Publication US 2024/0350457 A1, Oct. 24, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/415 (2006.01); A61K 9/00 (2006.01); A61K 31/00 (2006.01); A61P 19/04 (2006.01); A61P 19/08 (2006.01); A61P 31/00 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/415 (2013.01) [A61K 9/0053 (2013.01); A61K 31/00 (2013.01); A61P 19/04 (2018.01); A61P 19/08 (2018.01); A61P 31/00 (2018.01); A61K 9/0014 (2013.01); A61K 45/06 (2013.01)]

30 Claims

1. A method of reducing heterotopic ossification in a subject with fibrodysplasia ossificans progressiva, said method comprising:

(a) (i) during a period when the subject is not experiencing any flare-up symptom orally administering daily to the subject an amount of 5 mg of palovarotene, or a pharmaceutically acceptable salt thereof, and (ii) during a period when the subject is experiencing at least one flare-up symptom orally administering to the subject an amount of 20 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of 28 days, and after the period of 28 days, an amount of 10 mg of palovarotene, or a pharmaceutically acceptable salt thereof, daily for a period of at least 56 days;

(b) determining that the subject is experiencing tolerance problems; and